Sharekhan

Jagsonpal Pharmaceuticals Ltd

Wed 21/05/2025,15:59:31 NSE: JAGSNPHARM

₹ 208.58 -2.16 (-1.02%)
BUY NOW Buy Jagsonpal Pharmaceuticals Ltd Stock

Open Free Demat and Trading account in 15 minutes

Home Stock Jagsonpal Pharmaceuticals Ltd

Wed 21/05/2025,16:1:0

Jagsonpal Pharmaceuticals Ltd

Wed 21/05/2025,15:59:31 | NSE : JAGSNPHARM

₹ 208.58-2.16 (-1.02%)

Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.

Market Data

Essential tool: analyze, trade, manage, decide.

Open

₹ 212.67

Previous Close

₹ 210.74

Volume

89980

Mkt Cap ( Rs. Cr)

₹1386.50

High

₹ 212.67

Low

₹ 207.98

52 Week High

₹ 328.04

52 Week Low

₹ 110.00

Book Value Per Share

₹ 29.66

Dividend Yield

1.18

Face Value

₹ 2.00

What’s Your Call?

Collective community sentiment on Jagsonpal Pharmaceuticals Ltd

Your Vote -

Buy

77.78%

Hold

11.11%

Sell

11.11%

77.78%

9 users have voted

Market Depth

How many stocks are available to buy or sell and at what prices.

Buy Order Quantity

100%

Sell Order Quantity

0%

Bid Price

Qty

208.58

260

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

260

Bid Price

Qty

0.00

0

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

0

Option Chain

Analyzes market sentiment, predicts Jagsonpal Pharmaceuticals Ltd' movement.

NO_RECORD_FOUND

News

Media spotlight triggers stock stock attention, sentiment.

  • Jagsonpal Pharma - Analysts/Institutional Investor Meet/Con. Call Updates

    13 May 2025, 3:22PM Jagsonpal Pharmaceuticals Limited has informed the Exchange about Transcript

  • Jagsonpal Pharma - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

    13 May 2025, 3:13PM Earnings Call Transcript for Jagsonpal Pharmaceuticals Limited Q4FY25 Earnings Conference Call held on May 7, 2025

  • Jagsonpal Pharma - Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent

    8 May 2025, 4:31PM JAGSONPAL PHARMACEUTICALS LIMITED has informed the Exchange about Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Tr

  • Jagsonpal Pharma - Copy of Newspaper Publication

    8 May 2025, 10:03AM Extract of Audited Standalone Financial Results Copy of Newspaper Advertisement

  • Jagsonpal Pharma - Analysts/Institutional Investor Meet/Con. Call Updates

    7 May 2025, 6:51PM Jagsonpal Pharmaceuticals Limited has informed the Exchange about Link of Recording

  • Jagsonpal Pharma - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

    7 May 2025, 6:41PM Audio Recording of Jagsonpal Pharmaceuticals Limited Q4 FY25 Earnings Conference Call on May 07, 2025 at 4:00 P.M.

  • Jagsonpal Pharma - Alteration Of Capital and Fund Raising-XBRL

    6 May 2025, 9:37PM JAGSONPAL PHARMACEUTICALS LIMITED has informed the Exchange regarding Allotment of Securities

  • Jagsonpal Pharma - Updates

    6 May 2025, 9:29PM 'Jagsonpal Pharmaceuticals Limited has informed the Exchange regarding Allotment of Equity Shares under the Jagsonpal Pharmaceuticals Limited Employee

  • Jagsonpal Pharma - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

    6 May 2025, 9:20PM Allotment of Equity Shares under the Jagsonpal Pharmaceuticals Limited Employee Stock Option Plan, 2022

  • Jagsonpal Pharma - Updates

    6 May 2025, 8:42PM Jagsonpal Pharmaceuticals Limited has informed the Exchange regarding grant of 37,500 ESOP Options.

  • Jagsonpal Pharma - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

    6 May 2025, 8:39PM Intimation of Grant of Employees Stock Options

  • Jagsonpal Pharma - Analysts/Institutional Investor Meet/Con. Call Updates

    6 May 2025, 8:34PM Jagsonpal Pharmaceuticals Limited has informed the Exchange about Presentation

  • Jagsonpal Pharma - Press Release

    6 May 2025, 8:29PM Jagsonpal Pharmaceuticals Limited has informed the Exchange regarding a press release dated May 06, 2025, titled ""Press Release"".

  • Jagsonpal Pharma - Announcement under Regulation 30 (LODR)-Press Release / Media Release

    6 May 2025, 8:26PM Please find enclosed press release and Investor Presentation for the quarter and year ended March 31, 2025.

  • Jagsonpal Pharma - Outcome of Board Meeting-XBRL

    6 May 2025, 8:20PM Jagsonpal Pharmaceuticals Limited has informed the Exchange regarding Outcome of Board Meeting held on 06-May-2025 for Dividend

  • Jagsonpal Pharma - Updates

    6 May 2025, 7:58PM Jagsonpal Pharmaceuticals Limited has informed the Exchange regarding 'Termination of Business Transfer Agreement Disclosure under Regulation 30 of

  • Jagsonpal Pharma - Termination Of Business Transfer Agreement - Disclosure Under Regulation 30 Of SEBI Listing Regulations

    6 May 2025, 7:57PM Termination of Business Transfer Agreement- Disclosure under Regulation 30 of SEBI Listing Regulations

  • Jagsonpal Pharma - Corporate Action-Board approves Dividend

    6 May 2025, 7:49PM The board of directors at its meeting held today has recommended a dividend of Rs. 2.5/- (125%) per equity share of face value of Rs. 2/- for the fina

  • Jagsonpal Pharma - Updates

    6 May 2025, 7:44PM Jagsonpal Pharmaceuticals Limited has informed the Exchange regarding 'Dividend Updates'.

  • Jagsonpal Pharma Q4 net profit jumps 85.35% at Rs 6.58 cr

    6 May 2025, 7:30PM The company reported standalone net profit of Rs 6.58 crore for the quarter ended March 31, 2025 as compared to Rs 3.55 crore in the same period last

  • Jagsonpal Pharma - Audited (Standalone) Financial Results For The Year Ended March 31, 2025

    6 May 2025, 7:29PM Audited (Standalone) Financial Results for the year ended March 31, 2025

  • Jagsonpal Pharma - Dividend

    6 May 2025, 7:19PM Jagsonpal Pharmaceuticals Limited has informed the Exchange that Board of Directors at its meeting held on May 06, 2025, recommended Final Dividend of

  • Jagsonpal Pharma - Outcome of Board Meeting

    6 May 2025, 7:16PM Jagsonpal Pharmaceuticals Limited has informed the Exchange regarding Outcome of Board Meeting held on May 06, 2025.

  • Jagsonpal Pharma - Board Meeting Outcome for Outcome Of Board Meeting Held On May 06, 2025 Along With Audited (Standalone) Fi

    6 May 2025, 6:53PM Pursuant to Regulation 30 (read with Part A of Schedule III) and Regulation 33 of the Securities and Exchange Board\r\nof India (Listing Obligations a

  • Jagsonpal Pharma - Analysts/Institutional Investor Meet/Con. Call Updates

    30 Apr 2025, 3:25PM Jagsonpal Pharmaceuticals Limited has informed the Exchange about Schedule of meet

  • Jagsonpal Pharma - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    30 Apr 2025, 3:14PM Intimation of Analysts/Investors Conference call on Wednesday May 07, 2025, to discuss Q4 FY 25 financial results.

  • Jagsonpal Pharma - Board Meeting Intimation

    29 Apr 2025, 5:04PM JAGSONPAL PHARMACEUTICALS LIMITED has informed the Exchange about Board Meeting to be held on 06-May-2025 to consider and approve the Yearly Audited F

  • Jagsonpal Pharma - Board Meeting Intimation for Consideration Of Financial Results For The Quarter And Year Ended March 31, 2

    29 Apr 2025, 4:53PM Jagsonpal Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/05/2025 ,inter alia, to con

  • Jagsonpal Pharma - Spurt in Volume

    28 Apr 2025, 9:03AM Significant increase in volume has been observed in Jagsonpal Pharmaceuticals Limited. The Exchange, in order to ensure that investors have latest rel

  • Jagsonpal Pharma - Clarification On Significant Increase In The Volume

    28 Apr 2025, 12:53PM Clarification on Significant Increase in the Volume

  • Jagsonpal Pharma - Clarification On Significant Increase In Volume Of Security Of The Company, Required By NSE

    28 Apr 2025, 9:10AM Clarification on Significant increase in volume of security of the Company, Required by NSE

  • Jagsonpal Pharma - Spurt in Volume

    25 Apr 2025, 5:46PM Significant increase in volume has been observed in Jagsonpal Pharmaceuticals Limited. The Exchange, in order to ensure that investors have latest rel

  • Jagsonpal Pharma - Alteration Of Capital and Fund Raising-XBRL

    21 Apr 2025, 12:11PM JAGSONPAL PHARMACEUTICALS LIMITED has informed the Exchange regarding Allotment of Securities

  • Jagsonpal Pharma - Updates

    21 Apr 2025, 12:06PM Jagsonpal Pharmaceuticals Limited has informed the Exchange regarding ''.

  • Jagsonpal Pharma - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

    21 Apr 2025, 11:57AM Allotment of Equity Shares under the Jagsonpal Pharmaceuticals Limited Employee Stock Option Plan, 2022

  • Jagsonpal Pharma has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2025

    18 Apr 2025, 8:10PM As of March 2025, 67.78% is owned by Promoters and 32.22% by Public. <p align=justify> Among Promoters holding, Indian Promoters holds 24.64% and Fore

  • Jagsonpal Pharma - Certificate under SEBI (Depositories and Participants) Regulations, 2018

    8 Apr 2025, 1:38PM Jagsonpal Pharmaceuticals Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018

  • Jagsonpal Pharma - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    8 Apr 2025, 1:34PM Compliance Certificate under Reg 74(5) of SEBI (DP) Regulations, 2018

  • Jagsonpal Pharma - Action(s) initiated or orders passed

    2 Apr 2025, 6:00PM Jagsonpal Pharmaceuticals Limited has informed the Exchange about Action(s) initiated or orders passed

  • Jagsonpal Pharma - Trading Window-XBRL

    26 Mar 2025, 4:00PM JAGSONPAL PHARMACEUTICALS LIMITED has informed the Exchange about Closure of Trading Window

  • Jagsonpal Pharma - Trading Window-XBRL

    26 Mar 2025, 3:57PM JAGSONPAL PHARMACEUTICALS LIMITED has informed the Exchange about Closure of Trading Window

  • Jagsonpal Pharma - Trading Window

    26 Mar 2025, 3:55PM Jagsonpal Pharmaceuticals Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Reg

  • Jagsonpal Pharma - Alteration Of Capital and Fund Raising-XBRL

    13 Mar 2025, 5:55PM JAGSONPAL PHARMACEUTICALS LIMITED has informed the Exchange regarding Allotment of Securities

  • Jagsonpal Pharma - Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent

    13 Mar 2025, 5:53PM JAGSONPAL PHARMACEUTICALS LIMITED has informed the Exchange about Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Tr

  • Jagsonpal Pharma - Updates

    13 Mar 2025, 4:32PM Jagsonpal Pharmaceuticals Limited has informed the Exchange regarding 'Allotment of Equity Shares under the Jagsonpal Pharmaceuticals Limited Employee

  • Jagsonpal Pharma - Updates

    13 Mar 2025, 4:05PM Jagsonpal Pharmaceuticals Limited has informed the Exchange regarding 'Intimation under Regulation 30(5) of the SEBI (Listing Obligations and Disclosu

  • Jagsonpal Pharma - Change in Company Secretary/Compliance Officer

    13 Mar 2025, 3:49PM Jagsonpal Pharmaceuticals Limited has informed the Exchange about Change in Company Secretary/Compliance Officer

  • Jagsonpal Pharma - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

    13 Mar 2025, 4:24PM Allotment of Equity Shares under the Jagsonpal Pharmaceuticals Limited Employee Stock Option Plan, 2022

  • Jagsonpal Pharma - Intimation Under Regulation 30(5) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulation

    13 Mar 2025, 4:00PM We wish to inform you that consequent to the appointment of Mr. Pratham Rawal as Company Secretary, the board of directors have approved changes in KM

  • Jagsonpal Pharma - Appointment of Company Secretary and Compliance Officer

    13 Mar 2025, 3:41PM Appointment of Mr. Pratham Rawal as Company Secretary and Compliance Officer of the Company w.e.f. March 13, 2025

  • Jagsonpal Pharma - Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent

    3 Mar 2025, 7:23PM JAGSONPAL PHARMACEUTICALS LIMITED has informed the Exchange about Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Tr

  • Jagsonpal Pharma - Change in Company Secretary/Compliance Officer

    3 Mar 2025, 7:00PM Jagsonpal Pharmaceuticals Limited has informed the Exchange about Change in Company Secretary/Compliance Officer

  • Jagsonpal Pharma - Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance Officer

    3 Mar 2025, 7:00PM Please find enclosed herewith resignation submitted by Mr. Abhishek Joshi, as Company Secretary and Compliance Officer & Key Managerial Personnel of t

  • Jagsonpal Pharma - Clarification In Reference To The Corporate Announcement Filed Under Regulation 30 Of SEBI (LODR) Regulati

    27 Feb 2025, 6:37PM Please find enlcosed herewith response to additional details required under SEBI Circular dated November 11, 2024 for corporate Announcement filed und

  • Jagsonpal Pharma - General Updates

    21 Feb 2025, 7:44PM Jagsonpal Pharmaceuticals Limited has informed the Exchange about acquisition of e wish to inform you that Jagsonpal Pharmaceuticals Limited has signe

  • Jagsonpal Pharma - Announcement under Regulation 30 (LODR)-Acquisition

    21 Feb 2025, 7:37PM In compliance with Regulation 30 read with Schedule III of the Listing Regulations read with SEBI Master Circular. We wish to inform you that Jagsonpa

  • Jagsonpal Pharma - Action(s) taken or orders passed

    21 Feb 2025, 6:32PM Jagsonpal Pharmaceuticals Limited has informed the Exchange about Action(s) taken or orders passed

  • Jagsonpal Pharma - Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015

    21 Feb 2025, 6:23PM With reference to the above we wish to inform you that Company had received the warning letter dated February 05, 2025 from USFDA regarding observatio
Load More
Show Less

Key fundamentals

Evaluate the intrinsic value of Jagsonpal Pharmaceuticals Ltd stock 

Name March-25 March-24 March-23 March-22 March-21
Assets 239.95 187.402 158.89 130.8556 128.717
Liabilities 239.95 187.402 158.89 130.8556 128.717
Equity 13.28 13.219 13.099 13.099 13.099
Gross Profit 51.071 23.067 34.151 25.7944 19.0785
Net Profit 55.361 22.463 26.721 19.587 17.0583
Cash From Operating Activities 55.3 35.166 46.655 5.5981 28.2224
NPM(%) 20.6 10.76 11.28 8.66 9.07
Revenue 268.716 208.702 236.714 226.0967 187.9456
Expenses 217.645 185.635 202.563 200.3023 168.8671
ROE(%) 28.07 11.39 13.55 9.93 8.65

Shareholding Pattern

Corporate Action

XD-Date Dividend-Amount Dividend-% Dividend Yield(%GE) Price on that day
2.5 125 1.2 240.58
06 Sep 2024 5 100 1.2 351.15
21 Aug 2023 5 100 1.2 352.9
29 Oct 2021 4 80 1.2 162.15
22 Sep 2021 1 20 1.2 157.65
22 Sep 2020 0.5 10 1.2 35.15
20 Sep 2019 0.25 5 1.2 27.1
18 Sep 2018 0.1 2 1.2 26.7
21 Sep 2017 0.1 2 1.2 38.4
21 Sep 2016 0.1 2 1.2 33.85
21 Sep 2015 0.1 2 1.2 26.5
25 Sep 2014 0.5 10 1.2 23.65
25 Sep 2013 0.5 10 1.2 9.5
21 Sep 2012 0.5 10 1.2 12.35
23 Sep 2011 0.5 10 1.2 12.55
21 Sep 2010 0.5 10 1.2 23.85
23 Sep 2009 0.25 5 1.2 12.45
24 Sep 2008 0.1 2 1.2 13.4
21 Sep 2007 0.1 2 1.2 16.7
26 Sep 2006 0.1 2 1.2 19.25
26 Sep 2005 1 20 1.2 55.45
27 Aug 2004 0.5 10 1.2 244.25
30 May 2003 3.75 37.5 1.2 81.15
05 Mar 2002 0 20 1.2 111.85
11 Sep 2001 0 30 1.2 330
0 30 1.2 199

Peers

Other companies within the same industry or sector that are comparable to Jagsonpal Pharmaceuticals Ltd

Company Price Price (% change) pe(x) EV/EBITDA(x) ROE(%) ROCE(%)
Albert David Ltd 810.15 -0.84 26.88 120.11 301.39 0.62
Lotus Eye Hospital and Institute Ltd 74.06 0.78 308.58 437.66 14.01 0.68
Vaishali Pharma Ltd 12.85 -1.15 428.33 225.59 2.76 0.00
Astec Lifesciences Ltd 701.25 -1.59 0.00 412.67 -687.11 0.00

Company Info

1995 - The Company is well poised to venture into new areas of activity which will propel it into achieving its projected goals. 1998 - The company is all set to realise it's laid-out expansion plans and gain substantially, both in sales volume and profits, with its proposed new product introductions, in the year. 1999 - The Company launched/re-launched a few products, which have been well received in the market. - The Company raised funds to the tune of Rs.5 crores through issue of 5,00,000 16% Non-Convertible Secured Debentures of Rs. 100 each to Life Insurance Corporation of India, General Insurance Corporation of India (GIC) and four subsidiaries of GIC. - The company is manufacturing off-patent drugs, where the entry barriers are relatively low. - The company has entered into tie-ups to make a range of anti-oxidants and hormones which are expected to be launched in 1999-2000. 2000 - The Company is having in-house share transfer and related facilities at the Registered office New Delhi. The Company is entering into an agreement with NSDL and CDSL for dematerialisation. 2004 -Company has issued a bonus shares in the ratio of 3:1. 2011 -The company has recommended a dividend of Rs. 0.50 per equity shares. 2013 -The company has recommended a dividend of Rs. 0.50 per equity shares. -Mr. Raj Kumar Kapoor has been appointed as Compliance officer cum Company Secretary of the company. 2014 -The company has recommended dividend of Rs. 0.50/- per Equity share. 2024 -The Company has informed regarding Acquisition for signing Business Transfer Agreement for the purchase of India & Bhutan business of Yash Pharma Laboratories Pvt.Ltd. -The Company Launches MemUp India's First Bioidentical Hormone Replacement Therapy in a Single Pill.

1995 - The Company is well poised to venture into new areas of activity which will propel it into achieving its projected goals. 1998 - The company is all set to realise it's laid-out expansion plans and gain substantially, both in sales volume and profits, with its proposed new product introductions, in the year. 1999 - The Company launched/re-launched a few products, which have been well received in the market. - The Company raised funds to the tune of Rs.5 crores through issue of 5,00,000 16% Non-Convertible Secured Debentures of Rs. 100 each to Life Insurance Corporation of India, General Insurance Corporation of India (GIC) and four subsidiaries of GIC. - The company is manufacturing off-patent drugs, where the entry barriers are relatively low. - The company has entered into tie-ups to make a range of anti-oxidants and hormones which are expected to be launched in 1999-2000. 2000 - The Company is having in-house share transfer and related facilities at the Registered office New Delhi. The Company is entering into an agreement with NSDL and CDSL for dematerialisation. 2004 -Company has issued a bonus shares in the ratio of 3:1. 2011 -The company has recommended a dividend of Rs. 0.50 per equity shares. 2013 -The company has recommended a dividend of Rs. 0.50 per equity shares. -Mr. Raj Kumar Kapoor has been appointed as Compliance officer cum Company Secretary of the company. 2014 -The company has recommended dividend of Rs. 0.50/- per Equity share. 2024 -The Company has informed regarding Acquisition for signing Business Transfer Agreement for the purchase of India & Bhutan business of Yash Pharma Laboratories Pvt.Ltd. -The Company Launches MemUp India's First Bioidentical Hormone Replacement Therapy in a Single Pill.

Read More

Parent Organisation

Jagsonpal Pharmaceuticals Ltd.

Founded

17/08/1978

Managing Director

Mr.Manish Gupta

NSE Symbol

JAGSNPHARMEQ

FAQ

The current price of Jagsonpal Pharmaceuticals Ltd is ₹ 208.58.

The 52-week high for Jagsonpal Pharmaceuticals Ltd is ₹ 212.67 and the 52-week low is ₹ 207.98.

The market capitalization of Jagsonpal Pharmaceuticals Ltd is currently ₹ 1386.50. This value can fluctuate based on stock price movements and changes in the number of shares outstanding.

To buy Jagsonpal Pharmaceuticals Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.

To invest in Jagsonpal Pharmaceuticals Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Jagsonpal Pharmaceuticals Ltd shares.

The CEO of Jagsonpal Pharmaceuticals Ltd is Mr.Manish Gupta, who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.

OPEN FREE* DEMAT ACCOUNT